Search results
Showing 1 to 15 of 41 results for golimumab
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in